GeoVax Labs, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GOVX Nasdaq 2836 www.geovax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GeoVax Labs, Inc.

GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States - Sep 29th, 2026 6:37 am
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models - Sep 21st, 2026 6:37 am
GeoVax Confirms Bundibugyo Ebola Vaccine Construct - Sep 16th, 2026 6:37 am
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial - Sep 14th, 2026 6:37 am
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities - Sep 10th, 2026 6:37 am
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply - Sep 9th, 2026 7:00 am
GeoVax Announces a Warrant Inducement Transaction - Aug 26th, 2026 6:30 am
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation - Aug 25th, 2026 6:37 am
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak - Aug 24th, 2026 8:43 am
GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies - Aug 24th, 2026 6:37 am
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit - Aug 20th, 2026 7:00 am
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak - Aug 13th, 2026 9:00 am
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase - Aug 11th, 2026 7:00 am
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway - Aug 10th, 2026 3:02 pm
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study - Aug 6th, 2026 7:00 am
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio - Aug 3rd, 2026 7:00 am
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update - Jul 27th, 2026 2:00 pm
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy - Jul 21st, 2026 7:00 am
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness - Jul 1st, 2026 7:00 am
GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift - Jun 27th, 2026 8:07 am